Cargando…

RaDiCo, the French national research program on rare disease cohorts

BACKGROUND: Rare diseases (RDs) affect nearly 3 million people in France and at least 26–30 million people in Europe. These diseases, which represent a major medical concern, are mainly of genetic origin, often chronic, progressive, degenerative, life threatening and disabling, accounting for more t...

Descripción completa

Detalles Bibliográficos
Autores principales: Amselem, Serge, Gueguen, Sonia, Weinbach, Jérôme, Clement, Annick, Landais, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555205/
https://www.ncbi.nlm.nih.gov/pubmed/34715889
http://dx.doi.org/10.1186/s13023-021-02089-5
_version_ 1784591930879901696
author Amselem, Serge
Gueguen, Sonia
Weinbach, Jérôme
Clement, Annick
Landais, Paul
author_facet Amselem, Serge
Gueguen, Sonia
Weinbach, Jérôme
Clement, Annick
Landais, Paul
author_sort Amselem, Serge
collection PubMed
description BACKGROUND: Rare diseases (RDs) affect nearly 3 million people in France and at least 26–30 million people in Europe. These diseases, which represent a major medical concern, are mainly of genetic origin, often chronic, progressive, degenerative, life threatening and disabling, accounting for more than one third of all deaths occurring during infancy. In this context, there are needs for coordinated information on RDs at national/international levels, based on high quality, interoperable and sharable data. The main objective of the RaDiCo (Rare Disease Cohorts) program, coordinated by Inserm, was the development of RD e-cohorts via a national platform. The cohort projects were selected through a national call in 2014. The e-cohorts are supported by an interoperable platform, equivalent to an infrastructure, constructed on the "cloud computing" principle and in compliance with the European General Data Protection Regulation. It is dedicated to allow a continuous monitoring of data quality and consistency, in line with the French Health Data Hub. RESULTS: Depending on cohorts, the objectives are to describe the natural history of the studied RD(s), identify the underlying disease genes, establish phenotype-genotype correlations, decipher their pathophysiology, assess their societal and medico-economic impact, and/or identify patients eligible for new therapeutic approaches. Inclusion of prevalent and incident cases started at the end of 2016. As of April 2021, 5558 patients have been included within 13 RD e-cohorts covering 67 diseases integrated in 10 European Reference Networks and contributing to the European Joint Program on RDs. Several original results have been obtained in relation with the secondary objectives of the RaDiCo cohorts. They deal with discovery of new disease genes, assessment of treatment management, deciphering the underlying pathophysiological mechanisms, diagnostic approaches, genotype–phenotype relationships, development and validation of questionnaires relative to disease burden, or methodological aspects. CONCLUSION: RaDiCo currently hosts 13 RD e-cohorts on a sharable and interoperable platform constructed on the “cloud computing” principle. New RD e-cohorts at the European and international levels are targeted.
format Online
Article
Text
id pubmed-8555205
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85552052021-10-29 RaDiCo, the French national research program on rare disease cohorts Amselem, Serge Gueguen, Sonia Weinbach, Jérôme Clement, Annick Landais, Paul Orphanet J Rare Dis Research BACKGROUND: Rare diseases (RDs) affect nearly 3 million people in France and at least 26–30 million people in Europe. These diseases, which represent a major medical concern, are mainly of genetic origin, often chronic, progressive, degenerative, life threatening and disabling, accounting for more than one third of all deaths occurring during infancy. In this context, there are needs for coordinated information on RDs at national/international levels, based on high quality, interoperable and sharable data. The main objective of the RaDiCo (Rare Disease Cohorts) program, coordinated by Inserm, was the development of RD e-cohorts via a national platform. The cohort projects were selected through a national call in 2014. The e-cohorts are supported by an interoperable platform, equivalent to an infrastructure, constructed on the "cloud computing" principle and in compliance with the European General Data Protection Regulation. It is dedicated to allow a continuous monitoring of data quality and consistency, in line with the French Health Data Hub. RESULTS: Depending on cohorts, the objectives are to describe the natural history of the studied RD(s), identify the underlying disease genes, establish phenotype-genotype correlations, decipher their pathophysiology, assess their societal and medico-economic impact, and/or identify patients eligible for new therapeutic approaches. Inclusion of prevalent and incident cases started at the end of 2016. As of April 2021, 5558 patients have been included within 13 RD e-cohorts covering 67 diseases integrated in 10 European Reference Networks and contributing to the European Joint Program on RDs. Several original results have been obtained in relation with the secondary objectives of the RaDiCo cohorts. They deal with discovery of new disease genes, assessment of treatment management, deciphering the underlying pathophysiological mechanisms, diagnostic approaches, genotype–phenotype relationships, development and validation of questionnaires relative to disease burden, or methodological aspects. CONCLUSION: RaDiCo currently hosts 13 RD e-cohorts on a sharable and interoperable platform constructed on the “cloud computing” principle. New RD e-cohorts at the European and international levels are targeted. BioMed Central 2021-10-29 /pmc/articles/PMC8555205/ /pubmed/34715889 http://dx.doi.org/10.1186/s13023-021-02089-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Amselem, Serge
Gueguen, Sonia
Weinbach, Jérôme
Clement, Annick
Landais, Paul
RaDiCo, the French national research program on rare disease cohorts
title RaDiCo, the French national research program on rare disease cohorts
title_full RaDiCo, the French national research program on rare disease cohorts
title_fullStr RaDiCo, the French national research program on rare disease cohorts
title_full_unstemmed RaDiCo, the French national research program on rare disease cohorts
title_short RaDiCo, the French national research program on rare disease cohorts
title_sort radico, the french national research program on rare disease cohorts
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555205/
https://www.ncbi.nlm.nih.gov/pubmed/34715889
http://dx.doi.org/10.1186/s13023-021-02089-5
work_keys_str_mv AT amselemserge radicothefrenchnationalresearchprogramonrarediseasecohorts
AT gueguensonia radicothefrenchnationalresearchprogramonrarediseasecohorts
AT weinbachjerome radicothefrenchnationalresearchprogramonrarediseasecohorts
AT clementannick radicothefrenchnationalresearchprogramonrarediseasecohorts
AT landaispaul radicothefrenchnationalresearchprogramonrarediseasecohorts
AT radicothefrenchnationalresearchprogramonrarediseasecohorts